Abstract CT143: Phase I Study of the Combination of a RAF-MEK Inhibitor CH5126766 and FAK Inhibitor Defactinib in an Intermittent Dosing Schedule with Expansions in KRAS Mutant Cancers
Cancer Research（2020）
AI Read Science
Must-Reading Tree
Example
Generate MRT to find the research sequence of this paper
Chat Paper
Summary is being generated by the instructions you defined